Clarivate Plc (CLVT) Earnings Call Transcript & Summary
April 29, 2026
Earnings Call Speaker Segments
Mark Donohue
executiveThanks, and welcome, everyone. Good morning. We appreciate you being with us on this Clarivate First Quarter 2026 Earnings Conference Call. Please note that this call is being recorded and webcast, and it is the copyrighted property of Clarivate. Rebroadcasting any of this information, whether in whole or in part, requires prior written consent from Clarivate, and doing so without it is not allowed. The earnings call presentation that goes along with this is posted in the Investor Relations section of the company's website. On this call, we will be making certain forward-looking statements as defined under the applicable securities laws. Those forward-looking statements carry known and unknown risks, uncertainties and other factors that could cause the business's actual results, performance or achievements, or developments in Clarivate's industry, to differ materially from the anticipated results, performance, achievements or developments expressed or implied by such forward-looking statements. You can find information about the factors that cause actual results to differ materially from anticipated results or performance in Clarivate's filings with the SEC and on the company's website. Our discussion will include non-GAAP measures, or adjusted numbers. Clarivate believes non-GAAP results are useful in order to enhance understanding of our ongoing operating performance, but they are a supplement to and should not be considered in isolation from or as a substitute for GAAP financial measures. Reconciliations of these measures to GAAP measures are available in the earnings release and supplemental presentation on our website. Joining me today are Matti Shem Tov, Chief Executive Officer; and Jonathan Collins, Chief Financial Officer. Following our prepared remarks, we'll open up the call to your questions. And with that, it's a pleasure to turn the call over to Matti.
Matti Tov
executiveHello everyone, and thanks for being here today. I'll take you through how we performed in Q1, where we stand on our value creation plan, and the way execution throughout the company is setting Clarivate up for better organic revenue growth, wider margins, and stronger free cash flow generation; that makes five quarters in a row of improving results. The year has begun well, and I'm happy to say our Q1 financial results keep us on track to hit our full-year guidance. Revenue came in at $586 million, lifted by ongoing VCP momentum and delivery across the portfolio. Looking at growth, the quality of what makes up our revenue keeps getting better. Organic ACV growth reached 1.6%, while organic subscription revenue grew 1.7%, which reflects more customers adopting subscription-based solutions throughout Clarivate. We're encouraged by the underlying momentum we're seeing thanks to tighter alignment between how we sell and our product strategy. Adjusted EBITDA totaled $241 million, a 41% margin, nearly 200 basis points higher than a year ago, which shows what our subscription-first strategy and cost discipline are delivering. Free cash flow generation was solid too, at roughly $79 million, letting us pay down $143 million of debt in the quarter. Most importantly, the value creation plan is delivering. Every pillar is showing solid execution on our end, and you can see that in quicker uptake of products, stronger sales performance, and an accelerating cadence of launches. What we accomplished this quarter gives us greater conviction that the actions we've already put in motion are beginning to yield results that are more consistent, healthier margins, and powerful generation of free cash flow. Let me remind everyone that the value creation plan came out in early 2025, with the goal of tightening our focus, moving faster on execution, and creating lasting value for shareholders. Four central pillars support that plan: optimizing the business model, sharpening how we sell, speeding up AI innovation, making use of the proprietary data assets we own, and rationalizing the portfolio. Those pillars come through plainly in our financials by way of the subscription mix, expanding margins, and a lower debt load. For recurring revenue growth, Academia & Government continues to be a powerful driver. Across each of the three pillars in our value creation plan, execution is solid and the signs of advancement are unmistakable. Model optimization is accelerating our transition to subscription-based offerings. Our progress subscription solution keeps gaining traction—more than 600 new subscriptions were sold over the past 12 months—which underscores how durable and predictable our revenue base has become. Better cross-sell execution spanning content, research and analytics, and software solutions is also lifting our sales performance. Several important wins were closed this quarter, among them a multiproduct institutional agreement with Fuyao University, a newly established research-focused university in China. Our presence in China is growing, which shows we can provide integrated solutions and meet a wider range of customer needs. We're also harnessing AI, and it's delivering value customers can actually measure. With Clarivate Academic AI solutions, essential library workflows are being optimized—manual repetitive work has dropped by 30% to 60%, while throughput has doubled or even quadrupled. That illustrates how combining AI with climate-specific content and deep domain expertise produces a significant operational benefit for customers. Turning to Intellectual Property: execution and the fundamentals remain our clear focus, and there are positive indications that our stronger emphasis on new subscriptions and renewal discipline is producing results. In Q1, renewal rates rose by about 100 basis points, which helped push organic ACV trends to nearly flat. That marks a clear step up from earlier trends and backs our confidence that the IP business is progressing and getting back to sustainable recurring growth. Sales execution keeps getting stronger. Take national IP offices, the U.S. PTO among them, where we landed major trademark analytics contracts and large-scale digitization programs; these wins are advancing patent and trademark operations around the world and reinforce Clarivate's role as a long-term strategic partner in the IP ecosystem and analytics. This quarter, we rolled out brand image search, which brings in sophisticated AI features such as clustering and multilingual support. Thanks to these improvements, our IT professionals can spot insights, evaluate risk, and reach decisions more quickly and with greater confidence on a worldwide basis. Taken together, the IP segment now operates with greater focus and discipline, and we feel this momentum positions the business for growth ahead. Over in Life Science & Health, the value creation plan continues to show steady movement. Shifting from transactional selling to subscriptions remains on schedule, supported by encouraging customer responses and steadier sales trends. The effective changes we've implemented are reflected in organic revenue growth of nearly 1% for the first quarter. One thing worth highlighting: we brought on board a new customer that ranks among the top 20 global pharmaceutical companies for DRG Fusion, which is our newly launched platform for real-world data analytics. That win underscores how compelling our value proposition is when it comes to large, sophisticated buyers. We also closed subscription deals in the six-figure range with a biotech company for OpEx — the platform we offer for safety intelligence in preclinical and clinical settings — which shows that momentum keeps building across different customer sizes and use cases. Turning to Innovation, we're steadily widening access to our trusted regulatory and scientific intelligence by way of strategic partnerships. This quarter, we connected Cortellis regulatory intelligence with Anthropic Cloude Enterprise, bringing together Clarivate's proprietary data and advanced AI reasoning so that trusted insight reaches customers right inside their AI workflows. This partnership highlights the way Clarivate is broadening both the reach and the relevance of this content throughout the wider AI ecosystem. Back in February, we shared that we are actively working toward selling the Life Science & Healthcare business, which forms part of our larger effort to rationalize the portfolio. That aligns with our wider strategy of directing capital and management attention toward the areas delivering the strongest returns. The process is still underway. As is always the case, the outcome cannot be guaranteed, and we will share updates when it makes sense to do so. Our goal has not changed: to maximize shareholder value while also sharpening our strategic focus on the businesses that remain. On earlier earnings calls, we have discussed the investments we are making in product innovation. At this point, I'd like to emphasize the way we're expanding AI deployment throughout Clarivate to generate efficiency gains and help speed up free cash flow growth. That effort sits at the heart of our value creation plan and serves as a major lever for margin expansion as we get back to stronger organic growth. Let me offer some detail and a few examples. On the go-to-market side, we're integrating AI into sales and customer care in order to speed revenue growth, make customer interactions more efficient, lift service quality and experience, and boost retention. When it comes to technology, we're putting AI to work across software engineering and content operations so innovation moves faster and new products reach the market sooner. In our corporate functions, we're applying AI in finance, human resources, and legal to automate workflows and achieve efficiencies that scale. We anticipate that rolling out digital agents will cut manual effort, raise accuracy, and generate operating leverage. Taken together, these AI-driven cost efficiencies strengthen our core messages. As organic growth picks up, this AI efficiency gives us confidence in lasting margin expansion and rising cash flow. To wrap up, Q1 demonstrates that the actions taken as part of our value creation plan are driving improved execution, firmer fundamentals, and a more defined road forward. We're operating with greater focus, strengthening our business model, improving how effectively we sell, and delivering meaningful innovation to customers, all while maintaining strict control over costs and cash generation. We appreciate your continued support and are eager to share our progress with you going forward. At this point, I'll turn things over to Jonathan, who will walk through our financial results and outlook.
Jonathan Collins
executiveThanks, Matti. On Slide 14, you'll see a summary of how we performed in Q1 versus the same quarter a year ago. Revenue for the quarter came to $586 million, and the swing from the year-ago period reflected the divestitures we made, though that was partly countered by organic gains and a helpful move in foreign exchange. Our net loss for Q1 stood at $40 million. That $64 million gain versus last year came from a favorable FX benefit, along with reduced restructuring charges, lower income tax, and less interest expense. Adjusted diluted EPS climbed almost 30%, or $0.04, from a year earlier, landing at $0.18. That improvement came from growth in adjusted EBITDA, reduced interest expense, a smaller tax bill, and fewer shares outstanding thanks to last year's buybacks — each of those added roughly $0.01. Operating cash flow for the quarter totaled $135 million. Versus last year, the shift came from more working capital tied to incentive compensation payouts, partly made up for by stronger adjusted EBITDA. Now let's move to Page 15, where we break down what drove the top and bottom line changes in Q1 relative to a year ago. Three main things explain the year-over-year moves: First, organic revenue posted modest growth, with subscription gains of almost 2% partly canceled out by weaker recurring and transactional revenue. That expansion translated into robust earnings, because expenses ended up lower than the prior year despite bringing in more money, as efficiencies were identified across the organization. Next, the units slated for sale reduced sales by $24 million, but savings from shutting them down offset almost the entire amount, resulting in adjusted EBITDA being $3 million lower on a net basis. Lastly, compared with the first quarter of the previous year, the U.S. dollar weakened slightly versus a group of other currencies, which gave revenue a favorable FX effect. The profit conversion in the mid-teens range comes from transaction gains recorded a year ago that were not repeated. All told, tight cost control pushed adjusted EBITDA margin up by almost 200 basis points, right in line with our guidance for the full year. Let's turn to Page 16 now to see how adjusted EBITDA turned into free cash flow and how we put that capital to work. Free cash flow in Q1 was $79 million, down $31 million from a year ago. The reason was more working capital from incentive compensation payments, partly offset by adjusted EBITDA growth; we took that free cash flow plus extra cash on hand to redeem the last $100 million of bonds maturing later in 2023, buy back $43 million of bonds coming due in 2028 and 2029 at a blended discount near 10%, and repurchase 7 million shares to counter the dilution from stock compensation investing. Now let's go to Page 17, where you'll see our full-year financial guidance, and nothing in it has changed at all since February. We're reconfirming today our full-year financial outlook across every metric. Up at the top of that page, we believe the pickup in organic annual contract value that we saw last year will carry into 2026, producing growth somewhere between 2% and 3%, which works out to roughly 0.75 percentage point more at the midpoint of that range and keeps us on a steady path of progress; at the midpoint we're looking for recurring organic growth of approximately 1.5%, nearly 1 percentage point better than a year ago. Purely because of the wind down of the businesses being disposed of, revenue at the midpoint should come in about $100 million lower, at $2.36 billion, and our organic recurring revenue mix, once the impact of those disposals is excluded, should rise to a range of 88% to 90%. Further down, even with that smaller revenue, we see adjusted EBITDA posting modest growth, lifting our profit margin to close to 43% at the midpoint; at the midpoint, adjusted diluted EPS should be up roughly 9%, reaching $0.75, mostly thanks to the share repurchases we finished last year. And free cash flow, at the midpoint, should rise approximately 10%, to $400 million. If you turn to Page 18, you'll see a summary of the anticipated full-year top and bottom line movements compared with last year. Looking at the midpoints of our ranges, adjusted EBITDA margin ought to expand by approximately 200 basis points, and the forces behind that are resumed organic growth, continued cost discipline, and completing the disposals. We're looking for organic growth of roughly 1%, with subscription revenue growth leading the way as ACV continues to accelerate. To completely counter inflation, we have cost efficiency plans ready, which means the roughly $25 million in added revenue should flow through entirely to profit. Roughly 1/3 of the profit margin expansion will come from this. We anticipate that divestitures of non-core assets will reduce our top line by roughly $130 million for the current year, while we are cutting operating costs by over $100 million, producing a bottom-line effect of around $25 million and accounting for the other two-thirds of the margin improvement. Keep in mind that our outlook for this year is built on the assumption that the LS&H business remains ours for all twelve months, so should a deal to divest that business be finalized, we might need to update our guidance for this potential transaction at some point later in the year. We still expect foreign exchange translation to give a modest boost to revenue and profit — $10 million on the top line and $5 million on the bottom line — and we've already seen most of that in Q1. If you'll turn with me to Page 19, we'll go through how we expect seasonality to shape revenue and profit this year — a view we've refined now that we've seen our first-quarter results — and we continue to expect steady gains in both revenue and profit as the year goes on. Back in February, we said we’d see a modest quarter-over-quarter dip in annual contract value organic growth during Q1, and that’s what happened; from here, we look for that metric to strengthen at a steady pace across the rest of the year, landing close to the middle of our range. In Q1, recurring organic revenue growth came in at 1%, which was better than we’d anticipated, mainly because of when patent renewals landed. Because of that timing, we’re expecting a modest step down in Q2, which then sets us up for faster growth during the latter half of the year. Looking ahead about six months, sales ought to remain roughly flat, then tick up in the fourth quarter, which mirrors the typical seasonal cadence we see in reoccurring and transactional revenues. On top of that, we anticipate margins continuing to expand throughout the remainder of the year, supported by organic growth as well as the impact of the disposals. Let's turn together now to Page 20, where we will walk through the path from over $1 billion in adjusted EBITDA to approximately $400 million in free cash flow, and explain our plans for deploying that capital.
Jonathan Collins
executiveAt the middle of our range, we anticipate free cash flow will increase roughly $35 million, or 10%, versus a year ago. We expect onetime costs to decline, mainly because restructuring expenses will be lower. As mentioned a couple of pages back, the sale of the LS&H segment is not included in our guidance. Should we finalize an agreement, that's something we would provide an update on later in the year; we expect cash interest to get better by roughly $20 million compared with the prior year, driven by the debt we prepaid last year and in the last quarter. That's also due to additional debt we intend to prepay during the rest of this year, plus some savings tied to the projected forward base rate curve. Cash taxes should come in $5 million to $10 million above last year, mostly because of the new corporate tax in Jersey; we expect the change in working capital this year to be a use of about $20 million, largely from incentive compensation payments in Q1. We're also anticipating a $10 million benefit from lower impaired contractual costs. And although we stay committed to investing in product innovation, the disposals and cost efficiencies will boost capital spending by roughly $15 million. When it comes to capital allocation, we intend to direct the free cash flow we produce for the rest of the year toward reducing debt. Now please join me on Page 21 for additional details about our deleveraging plan for this year and beyond. The chart at the top of that page lays out our debt maturity profile. As you can see, we have an attractive runway with nothing maturing in the near term. Across the last 3 years, '23 through '25, we produced $1.2 billion in cumulative free cash flow, averaging just over $100 million each quarter. As I pointed out on the previous page, we expect to produce roughly $400 million this year at the midpoint of our range, and we expect to produce no less than that amount next year and the year after. This outlook yields a comparable average quarterly rate of about $100 million. With today's debt market conditions, we intend to apply our free cash flow going forward to retiring our bonds early. During the next 9 quarters, we expect to redeem our secured notes completely ahead of their July '28 maturity. After those are redeemed, we intend to use our quarterly free cash flow to start retiring the '29 notes, which would leave just $0.5 billion of the $1.8 billion in mid-term maturities that needs refinancing over the next few years; it's worth noting that, like all of our forward-looking guidance, this outlook includes our LS&H business. If the potential sale does happen, we expect it would remove the need for a future bond refinancing. We anticipate these debt reduction actions will bring our net leverage down from 4 turns at the end of Q1 this year to about 2.5 turns within a few years. The better outcomes we're achieving as we put the value creation plan into action, along with the lasting cash flows we produce, keep giving us a lot of encouragement. To wrap up, I want to express my gratitude to everyone for joining us this morning. At this point, I'll hand the call back to the operator so your questions can be taken.
Toni Kaplan
analystThanks. You mentioned the new AI features you've rolled out, and how AI-driven efficiencies are cutting down on some of that repetitive manual labor. I'd love to hear about how these new AI offerings are gaining traction, what customers are saying, and how much growth they're driving right now. Also, can you put any numbers on the efficiency gains AI is bringing? That would be great. .
Matti Tov
executiveThanks, Toni. I'll kick things off, and Jonathan will pick it up from there. To begin with, over the past 15, 18 months we've been ramping up our spending, putting more and more into AI, and that happens in 2 ways. The first thing we did was a big product launch and innovation effort across the 3 segments. And now we're also pivoting, or shifting, toward internal cost efficiencies — that's AI too. When it comes to internal cost efficiencies, we see chances in go-to-market, customer support, and sales operations, and there are chances in technology to help us innovate and build products more quickly with AI's help. There are chances on the corporate side too, to streamline some corporate expenses, whether that's finance or general legal. So internally, there's plenty of opportunity. On the external side, the product and this <<inaudible>> patient, is bringing innovation to our customers in what really matters. So there are 3 buckets of product innovation we have around AI. One is the first wave of products we've upgraded, or AI assistant. Product by product, across many of our offerings, we've implemented — we've implemented a research assistant; we've implemented it in various products in ANG and then in life science, and we're doing the same with IP; that was Wave 1. Wave 2 was agent. We're rolling out AI agent capabilities across our products where it counts. And then, just coming back from some feedback we got from some measurement we did on implementing agentic AI within our Alma Prime lab reporter. Basically, we've managed to cut the manpower or quadruple the throughput for some of our customers using agentic AI capability, and that's only the beginning. And the third wave is ecosystem implementation. Ecosystem implementation. We all know that this generation, especially student researchers, but also life science scientists and IT professionals, are getting AI through the big LLM providers. So we've begun that journey. We announced about a month ago that we're working with Anthropic to deliver AI capabilities within Anthropic Enterprise Customers. Taking the CRI proprietary products we have, or CRI proprietary data we have, in collaboration with Anthropic, we're enabling consumption of this data inside the Anthropic environment in a way that turns the LLM into our sales agent — meaning our customers, right where they are. Beyond that, as we — yesterday we unveiled yet another offering from ANG, named Nexus Connect. Consider universities: they license a wide variety of content, and once more, learners and researchers alike access that material via various kinds of LLMs. Nexus Connect is the fresh solution from ANG that takes the data into ChatGPT, Copilot — whichever LLM you pick — leveraging our tech to deliver content — both ours and that of others — right to our customers' fingertips. So all in all, tremendous energy and substantial resources are being channeled toward AI innovation; and as you're aware, we've recently received external acknowledgment that we're the leading fund in AI innovation within the academic ecosystem. That was a lengthy response, but I'll hand things to Jonathan so he can discuss the financials a bit.
Jonathan Collins
executiveAbsolutely, Toni — thanks for raising that. Regarding how big the internal AI efficiency opportunity really is, we've already laid out which areas we're concentrating on, and right now we feel very good that this set of opportunities positions us well to keep widening our margins and increasing our cash flows. My guess is we'll try to size this out more thoroughly, probably at some point later this year.
Manav Patnaik
analystMatti, could you bring us up to speed on what you're seeing when it comes to competition out there? My guess is they're leveraging AI and making their offerings better too — and I'm wondering whether you've noticed anything different, or if there's a way to stack up what you're doing against what the market is doing? .
Matti Tov
executiveAs I believe I said a moment ago, beyond being known as an AI innovator, adoption of our AI offering is strong across all 3 segments; that's something we've talked about; we have — within ANG, over one institution is utilizing an academic KI solution, and I brought up Nexus Connect, where in Lab Science upwards of 10,000 researchers and users rely on some of our — some of our AI product innovation, among them — I mean, the Claude Anthropic collaboration we announced not long ago. Things are going well for us in IT too, thanks to the recent brand image we've rolled out. So we look — we're always looking ahead. Rather than fixating on our competition, we aim to set the scene, and our confidence in product innovation is high. A lot of us come out of a products and engineering background, and I'd say we're seeing considerable progress and creation coming from our customers across the various segments.
Scott Wurtzel
analystMatti, from what I gathered in your prepared remarks, you brought up the opportunity in China and growing the business there. Could you perhaps elaborate a bit more on that ANG space in China and what kind of port it opens up for you folks?
Matti Tov
executiveSure. China plays a major role in our AI — in the strength and results of our ANG offerings; we've just returned from a gathering with several of our leading Chinese sales executives; during the past year we closed 15 new web science deals in China; so strong momentum exists for ANG in China, particularly around web science and, more lately, in <<inaudible>> science research intelligence, plus certain development and collaboration efforts we're involved in. Our outlook on ANG prospects in China is quite positive — and not just ANG, but Life Science and IP as well; we're presently weighing various concepts, and we see more than 1 that we have, yet we're optimistic regarding both the China market.
Ashish Sabadra
analystPhil Chi here, filling in for Ashish Sabadra. It's really encouraging to watch the organic sales figures keep improving quarter after quarter. IP, I'd say, is still performing well even though the broader climate is somewhat subdued. You've mentioned before that you expect things to pick up, perhaps during the latter portion of '26 and into the early part of '27, as those old batch renewal cycles return — is that roughly the direction you foresee for this segment? On top of that, you've landed some impressive wins too. How do all of those pieces fit together, in your view?
Matti Tov
executiveI'll kick things off, and then I'll turn it over to Jonathan for additional input. First, let me remind everyone that within IP, we hold the leading market position; that's something we sometimes lose sight of. What's more, we're the sole company — and much of my attention and many of my conversations have centered on this; no other firm offers all 3 or 4 of the sub offerings we provide within IP. Our presence in OT is substantial. Our IPMS offerings are excellent, and our intelligence offerings are excellent too, covering both trademark and patent; we've brought on a fresh management team <<inaudible>> a new manager, and we've sharpened our focus considerably around 2 priorities. The first is sales execution; we've made certain adjustments or changes within our sales organization, renewals, territory alignment and other areas. — as a result, self-execution now carries far greater strength and sharper focus, and the second is AI innovation, where we're generating very strong momentum alongside the IP management team, risk Mark — that was one product we brought up; now we're discussing brand image search, which I also referenced. We feel confident that IP will return to growth going forward; and Jonathan, could you provide a bit more detail on this?
Jonathan Collins
executiveAbsolutely. Like Matti pointed out, our ongoing spending on AI—we're expecting that to assist in speeding up expansion for our subscription offerings in that area. So we mentioned that we've achieved some consistent advancement. We experienced a modest uptick in renewal rates during Q1, and our organic ACV is now nearly level after several years of shrinking; so that's solid movement thanks to the investments we're putting in there. The largest portion of the IP segment, the recurring revenue flow, meaning our patent renewal operation—that operation, 2 years back, fell by a few percent, then last year it was flat. In the first half of this year, because of the comps and some timing effects from the first half of last year, it'll be down a little; we anticipate that operation coming back to growth during the second half of this year and a strong path as we head into next year. Regarding market conditions, patent stock growth has gotten better across the last few years, and that's a solid leading indicator. And the team, as Matti mentioned, has performed very well on sales execution, strengthening our competitive standing within that portion of the market. So we're seeing ongoing improvement, and we're eager for stronger results from IP over the upcoming quarters and into next year. Appreciate the question, Will.
George Tong
analystThis quarter, transactional revenues fell off due to softer A&G activity. Could you expand on what you're observing in that area and what conditions would be required for A&G activity to recover?
Jonathan Collins
executiveSure. Appreciate the question, George. Well, our transaction revenues declined by a couple of percent during Q1. As you pointed out, ANG served as the main factor for the quarter. To begin, I'd note that across the entire year, our guidance factors in that the transactional business will see a modest dip relative to last year. So this matched our expectations; within the quarter, part of that in AMG stemmed from how software implementations were timed. That tends to be somewhat uneven from one quarter to the next. Then, looking at the whole year, since we keep achieving success in Life Sciences, with shifts over to subscription, we anticipate a bit of a drag on the transactional side. However, Q1's modest drop matched our projections. — and aligns with our outlook for the entire year. Going into next year, we'll keep developing that sales pipeline — with the software products, there's some chance to enhance that as we head into next year. But that was the main factor in Q1.
Andrew Nicholas
analystI wanted to dig in a bit further on AMG growth — that segment has held up quite nicely across the last several quarters. Inside that 2% organic growth and the anticipated improvement — is it research analytics and content aggregation that's really driving things? Or would you say growth is coming mostly from software? Or do all of them sit near that 2% figure? I'm just wondering whether there's a particular subsegment underneath where you see a stronger case for growth to accelerate.
Jonathan Collins
executiveYes. Appreciate that question, Andrew. From the standpoint of organic growth contribution, the bright spot for us recently within A&G has been what we've achieved in our research and analytics category, which our flagship product, <<inaudible>>, leads. As Matti mentioned when he spoke about AI innovation. That's where a great deal of the new innovation has entered the product. So we're quite encouraged by how the research assistant was adopted last year, along with certain agents we've rolled out that are drawing excellent feedback, for instance the literature review agent. And beyond that, we're very excited about the growth this year that the web science research intelligence platform will help drive; that's the new AI native multi-agent platform that assists in measuring research success throughout the university ecosystem. So what we've observed there leaves us really encouraged. The content business has stayed in that range and typically expands at or somewhat under the average for AMG. Meanwhile the software business is performing well, with very high renewal rates. We have some new product innovation taking place there that could help spark additional growth; those are the 3 main areas, though the standout performance really comes from our research and analytics category. Thanks for the question, Andrew.
Adam Parrington
analystI'll take the question from the fish line. Apologies in case I overlooked this, but regarding the slide deck, life sciences and health care, moving forward faster than planned, and the ship subscription — what does the subscription mix of the business look like right now? And how ought this shift to affect organic growth across the year?
Jonathan Collins
executiveYeah, Adam, I appreciate the question. Ours is the segment with the biggest share of transactional revenue. So as a quick reminder, our commercialization consulting practice, which resides within the Life Sciences business, plays a significant role in the go-to-market motion here, yet it generates a reduced organic recurring revenue mix inside Life Sciences. What Matti mentioned regarding Slide 10 is that we've kept investing in product innovation so as to move some of those solutions toward a subscription; we began noticing progress on that during last year, which carries on into this year, and we anticipate maintaining steady progress, turning that business more predictable with a larger renewal base annually to assist in accelerating it and bringing it back to growth. So it's a blend of the commercial motion, where our marketplace focus lies, plus the product innovation driving that forward. Thus, we anticipate seeing ongoing traction there. And as Matti said earlier, eventually, we believe the recurring revenue mix can reach the low 90s, and life science is going to lead in that regard. Thanks for the question, Adam.
Matti Tov
executivePerhaps just a few final words to close things out — as I said earlier during this call, the BCP plan is delivering results; this marks the fifth quarter in a row of gains. Our subscription mix now stands at 89%. Sales execution has improved on our end, and when it comes to innovation, we lead the industry. It's a real pleasure to be with you today, and we appreciate the time you've given us.
Mark Donohue
executiveWe appreciate everyone joining us; that brings our session to an end, and we anticipate addressing any additional inquiries you may have over the next few days. Thanks.
Operator
operatorThat brings us to the end of today's call. We appreciate you being with us. You can go ahead and disconnect your lines at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Clarivate Plc transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Clarivate Plc earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Clarivate Plc or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.